EUVIMEDSkopri EUVIMED
Crossref

Clinical‐data‐driven pharmacological framework in liver disease: From liver cirrhosis to hepatocellular carcinoma

Ki-Kwang Oh, Goo-Hyun Kwon, Jung-A Eom, Kyeong Jin Lee, Dong Joon Kim, Ki-Tae Suk iD

British Journal of Pharmacology · 2025

DOI: 10.1111/bph.70286 ↗

At a glance

Journal article in British Journal of Pharmacology, 2025. Written by Ki-Kwang Oh and 5 co-authors. Institution: Institute for Liver and Digestive Diseases, College of Medicine, Hallym University, Chuncheon, 24252, South Korea. Major MEDLINE topics: Carcinoma, Hepatocellular, Liver Neoplasms, Liver Cirrhosis. 86 references. Funded by: Bio Industrial Technology Development Program funded by the Ministry of Trade, Industry and Energy (MOTIE, Korea), Korea Institute for Advancement of Technology funded by the Ministry of Trade, Industry and Energy (MOTIE, Korea), The Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background and Purpose This study aimed to identify key effectors and their potential ligands relevant to liver cirrhosis (LC), hepatocellular carcinoma (HCC) and adjacent non‐tumour tissue (ANT; reflecting the tumour‐influenced yet non‐cancerous liver environment rather than true disease tissue) using clinical GEO data (GSE25097) within a systems pharmacology framework. Experimental Approach. Differentially expressed genes (DEGs;|log₂FC| > 1) were identified and visualised using R software in conjunction with the STRING database. Protein–protein interaction (PPI) networks were constructed, with up‐regulated and down‐regulated genes depicted as blue and red circles, respectively. Candidate ligands were screened from a repository of natural organic compounds (NOCs), focussing on flavonoids and alkaloids. Kaplan–Meier Plotter (KMP), molecular docking tests (MDT) and density functional theory (DFT) analyses were employed to ensure robustness. Key Results. A total of 123 down‐regulated and 146 up‐regulated genes were identified and mapped into PPI networks. Among these, CCNB1 , associated with the p53 signalling pathway, emerged as the most significantly up‐regulated gene across LC, HCC, and ANT tissues. Flavopiridol, a flavonoid‐based inhibitor, was initially highlighted; however, subsequent screening identified coronaridine hydroxyindolenine (CH), an alkaloid, as the most promising candidate. CH demonstrated superior binding affinity compared to flavopiridol in both MDT and DFT analyses. Conclusion and Implications The CH– CCNB1 complex exhibited high stability, indicating that CH may represent potential candidate warranting further study against LC, HCC and ANT.

Subjects

MeSH terms (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsLiver CirrhosisHumansMolecular Docking SimulationProtein Interaction MapsAlkaloidsFlavonoidsLigands

Author keywords

CCNB1GSE25097adjacent non‐tumour tissuecoronaridine hydroxyindoleninehepatocellular carcinomaliver cirrhosisp53 signalling pathway

Substances

AlkaloidsFlavonoidsLigands

Authors and institutions

  • Institute for Liver and Digestive Diseases, College of Medicine, Hallym University, Chuncheon, 24252, South Korea.

ORCID profiles: Ki-Tae Suk

Funding

  • Bio Industrial Technology Development Program funded by the Ministry of Trade, Industry and Energy (MOTIE, Korea)
  • Korea Institute for Advancement of Technology funded by the Ministry of Trade, Industry and Energy (MOTIE, Korea)
  • The Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology
  • Hallym University Research Fund

Cite

APA

Oh, K. K., Kwon, G. H., Eom, J. A., Lee, K. J., Kim, D. J., & Suk, K. T. (2025). Clinical‐data‐driven pharmacological framework in liver disease: From liver cirrhosis to hepatocellular carcinoma. British Journal of Pharmacology. https://doi.org/10.1111/bph.70286

Vancouver

Oh KK, Kwon GH, Eom JA, Lee KJ, Kim DJ, Suk KT. Clinical‐data‐driven pharmacological framework in liver disease: From liver cirrhosis to hepatocellular carcinoma. British Journal of Pharmacology. 2025. doi:10.1111/bph.70286

BibTeX
@article{Oh2025,
  author = {Oh, Ki-Kwang and Kwon, Goo-Hyun and Eom, Jung-A and Lee, Kyeong Jin and Kim, Dong Joon and Suk, Ki-Tae},
  title = {Clinical‐data‐driven pharmacological framework in liver disease: From liver cirrhosis to hepatocellular carcinoma},
  journal = {British Journal of Pharmacology},
  year = {2025},
  doi = {10.1111/bph.70286}
}
Start for free →